



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

April 6, 2016

**Location: Iowa Medicaid Enterprise
100 Army Post Road
Des Moines, Iowa 50315**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) DHS Recommendation Letter – December 2015
 - b) Public Comment Policy
3. Updates/News Relevant to Medicaid
 - a) CMS Medicaid Drug Rebate Program Notice, Release No. 172
 - b) Letter from US Senate on High-Priced Drugs
 - c) CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016 - Found at: [Morbidity and Mortality Weekly Report Recommendations and Reports](#)
4. IME Pharmacy Update
5. Prevalence Report Summary
6. Case Studies
7. Public Comment (See Conflict of Interest Disclosure Form)
8. Focus Studies/Provider Education Initiatives
 - a) Duplicate Benzodiazepines – Follow Up
 - b) High Dose Amphetamine IR – Follow Up
 - c) High Dose Methylphenidate IR – Follow Up
 - d) Anxiolytic Benzodiazepine Use without an SSRI or SNRI – Follow Up
 - e) Methadone Utilization – Updated
9. ProDUR Edits

a) Tramadol Utilization in Members under 18 years of Age

10. Public Comment (See Conflict of Interest Disclosure Form)

11. Prior Authorization

- a) Long-Acting Opioids – Initial Review
- b) Adalimumab (Humira[®]) for Hidradenitis Suppurativa – Initial Review - Updated
- c) Rifaximin (Xifaxan[®]) – Initial Review
- d) Ivabradine (Corlanor[®]) – Initial Review
- e) Deferasirox – Initial Review
- f) Eluxadoline (Viberzi[™]) – Initial Review
- g) Mepolizumab (Nucala[™]) – Initial Review
- h) Smoking Cessation Therapy - Update
- i) PCSK9 Inhibitors – Second Review
- j) Valsartan/Sacubitril (Entresto[™]) – Second Review
- k) Sodium Oxybate (Xyrem[®]) – Second Review
- l) Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents – Second Review
- m) Non-Parenteral Vasopressin Derivatives of Posterior Pituitary Hormone Products – Second Review

12. Miscellaneous

- a) DUR Digest Vol. 28, No. 2 – Second Review
- b) DUR Digest Vol. 28, No. 3 – Initial Review
- c) MedWatch

13. Executive Closed Session

- a) Approval of Minutes

14. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting June 1, 2016***
Learning Resource Center, West Des Moines, IA**